Review ArticlesPrecardiogenic Shock A New Clinical EntitySingh, Twinkle MD; Samson, Rohan MD; Ayinapudi, Karnika MD; Motwani, Ayush MD; Le Jemtel, Thierry H. MDAuthor Information From the Department of Cardiovascular Medicine, Tulane University Heart and Vascular Institute, New Orleans, LA. Disclosure: The authors declare no conflicts of interest. Correspondence: Twinkle Singh, MD, Tulane University Heart and Vascular Institute, 1430 Tulane Avenue, SL-48, New Orleans, LA 70112. E-mail: email@example.com. Cardiology in Review: July/August 2019 - Volume 27 - Issue 4 - p 198-201 doi: 10.1097/CRD.0000000000000237 Buy Metrics Abstract The pathogenesis of cardiogenic shock (CS) has evolved from an acute event due to a large myocardial infarction to a semiacute event due to rapid hemodynamic deterioration on a background of preexisting left ventricular systolic dysfunction. Pre-CS refers to the period of rapid hemodynamic deterioration that precedes overt CS with hypotension, inflammatory response, and end-organ failure. Mortality remains extremely high in CS and has not improved over the past decades. Pre-CS offers a unique opportunity to initiate early treatment that may result in better clinical outcomes. The present review addresses the definition, recognition, and management of pre-CS with the pharmacologic or mechanical support of the failing left ventricle. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.